• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

普萘洛尔在大鼠体内的蓄积动力学:米氏介导清除率与符合“酶改变假说”的清除率变化的比较

Accumulation kinetics of propranolol in the rat: comparison of Michaelis-Menten-mediated clearance and clearance changes consistent with the "altered enzyme hypothesis".

作者信息

Weber C, Stoeckel K, Lalka D

机构信息

Department of Pharmaceutics, School of Pharmacy, State University of New York at Buffalo 14222.

出版信息

Pharm Res. 1994 Mar;11(3):420-5. doi: 10.1023/a:1018921306200.

DOI:10.1023/a:1018921306200
PMID:8008710
Abstract

(+)-Propranolol was infused at two rates into the pyloric vein (a portal vein tributary) of 15 male Sprague Dawley rats until apparent steady-state conditions were established (i.e., 8 hr at each rate). One group (n = 7) received the high dose (40 micrograms/min/kg) first, and in the other group (n = 8) the low dose (20 micrograms/kg/min) was used to initiate treatment. Free and total serum concentrations of propranolol were measured. When the low dose was given first, the apparent steady-state concentrations achieved during low- and high-rate infusion steps were 166 +/- 37 and 774 +/- 235 ng/mL, respectively. These data are consistent with a simple Michaelis-Menten kinetic model and the key parameters of such a model (Vmax and Km) were estimated. However, a crucial test of such a model (and one which should give insight regarding the relevance of an "altered enzyme hypothesis") is to reverse the order of infusion steps since, in a system controlled by Michaelis-Menten kinetics, the same steady-state concentrations should be achieved regardless of the order in which infusion steps are given. When the sequence of infusion rates was reversed, steady-state concentrations were 492 +/- 142 and 298 +/- 79 ng/mL for the high and low infusion rates, respectively. Clearly, a history of high-dose exposure reduces the intrinsic clearance of total drug (CLss) during a subsequent low-dose exposure (i.e., the apparent steady-state levels during the low-dose pyloric vein infusions were significantly different; P < 0.001). When these data were corrected for plasma protein binding, the same trends emerged.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

将(+)-普萘洛尔以两种速率输注到15只雄性斯普拉格-道利大鼠的幽门静脉(门静脉分支)中,直至建立明显的稳态条件(即每种速率下持续8小时)。一组(n = 7)先接受高剂量(40微克/分钟/千克),另一组(n = 8)先使用低剂量(20微克/千克/分钟)开始治疗。测量了普萘洛尔的游离和总血清浓度。当先给予低剂量时,低速率和高速率输注阶段达到的表观稳态浓度分别为166±37和774±235纳克/毫升。这些数据与简单的米氏动力学模型一致,并估算了该模型的关键参数(Vmax和Km)。然而,对该模型的一个关键测试(也是一个能洞察“酶改变假说”相关性的测试)是颠倒输注步骤的顺序,因为在由米氏动力学控制的系统中,无论输注步骤的顺序如何,都应达到相同的稳态浓度。当颠倒输注速率顺序时,高速率和低速率输注的稳态浓度分别为492±142和298±79纳克/毫升。显然,高剂量暴露史会降低随后低剂量暴露期间总药物的内在清除率(CLss)(即低剂量幽门静脉输注期间的表观稳态水平有显著差异;P < 0.001)。当对这些数据进行血浆蛋白结合校正时,出现了相同的趋势。(摘要截断于250字)

相似文献

1
Accumulation kinetics of propranolol in the rat: comparison of Michaelis-Menten-mediated clearance and clearance changes consistent with the "altered enzyme hypothesis".普萘洛尔在大鼠体内的蓄积动力学:米氏介导清除率与符合“酶改变假说”的清除率变化的比较
Pharm Res. 1994 Mar;11(3):420-5. doi: 10.1023/a:1018921306200.
2
Pharmacokinetics of D-propranolol following oral, intra-arterial and intraportal administration: contrasting effects of oral glucose pretreatment.口服、动脉内和门静脉内给药后D-普萘洛尔的药代动力学:口服葡萄糖预处理的对比作用
Biopharm Drug Dispos. 1993 Apr;14(3):217-31. doi: 10.1002/bdd.2510140305.
3
Disposition of azole antifungal agents. I. Nonlinearities in ketoconazole clearance and binding in rat liver.唑类抗真菌剂的处置。I. 酮康唑在大鼠肝脏中的清除率和结合的非线性
Pharm Res. 1993 Mar;10(3):418-22. doi: 10.1023/a:1018996524141.
4
The influence of vitamin K3 treatment on the pharmacokinetics and metabolism of (+)-propranolol in the rat.维生素K3处理对大鼠体内(+)-普萘洛尔药代动力学及代谢的影响。
Drug Metab Dispos. 1992 Mar-Apr;20(2):288-94.
5
Pharmacokinetics of methysergide and its metabolite methylergometrine in the rat.麦角新碱及其代谢产物甲基麦角新碱在大鼠体内的药代动力学
Drug Metab Dispos. 1990 May-Jun;18(3):338-43.
6
Sigmoidal kinetics of CYP3A substrates: an approach for scaling dextromethorphan metabolism in hepatic microsomes and isolated hepatocytes to predict in vivo clearance in rat.CYP3A底物的S型动力学:一种将右美沙芬在肝微粒体和分离的肝细胞中的代谢进行标度以预测大鼠体内清除率的方法。
J Pharmacol Exp Ther. 1999 Jul;290(1):58-65.
7
Propranolol: pooled Michaelis-Menten parameters and the effect of input rate on bioavailability.
Clin Pharmacol Ther. 1985 May;37(5):481-7. doi: 10.1038/clpt.1985.76.
8
Determination of in vivo hepatic extraction ratio from in vitro metabolism by rat hepatocytes.通过大鼠肝细胞体外代谢测定体内肝脏提取率
Drug Metab Dispos. 1991 Sep-Oct;19(5):990-6.
9
Analysis of hepatic metabolism affecting pharmacokinetics of propranolol in humans.影响普萘洛尔在人体药代动力学的肝脏代谢分析。
Int J Pharm. 2008 Feb 12;349(1-2):53-60. doi: 10.1016/j.ijpharm.2007.07.019. Epub 2007 Jul 24.
10
Direct measurement of propranolol bioavailability during accumulation to steady-state.在达到稳态蓄积过程中对普萘洛尔生物利用度的直接测定。
Br J Clin Pharmacol. 1978 Oct;6(4):345-50. doi: 10.1111/j.1365-2125.1978.tb00862.x.

本文引用的文献

1
Dose-dependent elimination of propranolol and its major metabolites in humans.
J Pharm Sci. 1983 Jul;72(7):725-32. doi: 10.1002/jps.2600720703.
2
Effects of chlorpromazine on the disposition and beta-adrenergic blocking activity of propranolol in the dog.氯丙嗪对狗体内普萘洛尔的处置及β-肾上腺素能阻断活性的影响。
J Pharmacokinet Biopharm. 1984 Jun;12(3):333-49. doi: 10.1007/BF01061724.
3
Suicidal destruction of cytochrome P-450 during oxidative drug metabolism.
Annu Rev Pharmacol Toxicol. 1983;23:481-503. doi: 10.1146/annurev.pa.23.040183.002405.
4
The inhibitory effect of propranolol pretreatment on its own metabolism in the rat.普萘洛尔预处理对大鼠自身代谢的抑制作用。
J Pharmacol Exp Ther. 1981 Sep;218(3):575-81.
5
The disposition of propranolol. IV. A dominant role for tissue uptake in the dose-dependent extraction of propranolol by the perfused rat liver.
J Pharmacol Exp Ther. 1973 Sep;186(3):447-54.
6
Disposition of propranolol. V. Drug accumulation and steady-state concentrations during chronic oral administration in man.普萘洛尔的处置。V. 人体长期口服给药期间的药物蓄积和稳态浓度。
Clin Pharmacol Ther. 1973 Jul-Aug;14(4):487-93. doi: 10.1002/cpt1973144part1487.
7
Drug absorption and metabolism studies by use of portal vein infusion in the rat. II. Influence of dose and infusion rate on the bioavailability of propranolol.利用大鼠门静脉输注进行药物吸收和代谢研究。II. 剂量和输注速率对普萘洛尔生物利用度的影响。
Chem Pharm Bull (Tokyo). 1974 Jul;22(7):1639-45. doi: 10.1248/cpb.22.1639.
8
A nonlinear physiologic pharmacokinetic model: I. Steady-state.一种非线性生理药代动力学模型:I. 稳态
J Pharmacokinet Biopharm. 1985 Feb;13(1):73-92. doi: 10.1007/BF01073657.
9
Propranolol: pooled Michaelis-Menten parameters and the effect of input rate on bioavailability.
Clin Pharmacol Ther. 1985 May;37(5):481-7. doi: 10.1038/clpt.1985.76.
10
Nonlinear pharmacokinetics of unbound propranolol after oral administration.口服给药后游离普萘洛尔的非线性药代动力学。
J Pharm Sci. 1987 Jul;76(7):521-4. doi: 10.1002/jps.2600760706.